Valuation: Insulet Corporation

Market Cap 10.58B 9.47B 8.74B 7.91B 14.79B 1,007B 15.03B 104B 41.6B 527B 39.69B 38.85B 1,669B P/E 2026 *
24.9x
P/E 2027 * 20x
Enterprise Value 10.63B 9.52B 8.78B 7.95B 14.86B 1,012B 15.1B 105B 41.79B 530B 39.88B 39.03B 1,677B EV / Sales 2026 *
3.23x
EV / Sales 2027 * 2.75x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day+0.04%
1 week+2.59%
Current month+17.16%
1 month+17.16%
3 months-7.73%
6 months-11.20%
Current year-46.22%
1 week 146.62
Extreme 146.62
154.95
1 month 128.01
Extreme 128.01
154.95
Current year 126.4
Extreme 126.4
299.8
1 year 126.4
Extreme 126.4
354.88
3 years 126.4
Extreme 126.4
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 28/04/2025
Director of Finance/CFO 53 30/09/2025
Compliance Officer 50 01/12/2022
Director TitleAgeSince
Director/Board Member 61 27/07/2015
Director/Board Member 54 20/10/2020
Director/Board Member 55 18/10/2021
Date Insider Type Main position Quantity % Market Cap. Importance
1/10/26 Tax

Chief Financial Officer

-1,882 0.0027%
30/9/26 Free

Director

141 0.0002%
30/9/26 Free

Director

178 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+0.04%+2.59%-51.00%+16.91% 10.58B
+1.31%+2.57%-14.69%+14.37% 181B
-5.37%-3.01%-19.26%+13.45% 120B
-0.01%+2.00%+6.97%+39.08% 119B
+3.40%+1.71%-42.32%+9.52% 91.44B
+0.74%+0.83%-2.19%+80.01% 63.07B
-0.46%+0.42%+8.19%+82.97% 55.8B
+0.07%+0.02%+10.91%-20.77% 54.03B
-1.71%+1.39%-9.60%+43.34% 45.38B
+0.60%+2.42%-0.67%-6.05% 34.37B
Average -0.13%+0.73%-11.36%+27.28% 77.41B
Weighted average by Cap. -0.16%+0.79%-10.45%+26.12%

Financials

2026 *2027 *
Net sales 3.29B 2.94B 2.72B 2.46B 4.6B 313B 4.67B 32.4B 12.93B 164B 12.33B 12.07B 519B 3.73B 3.34B 3.08B 2.79B 5.22B 355B 5.3B 36.8B 14.68B 186B 14.01B 13.71B 589B
Net income 425M 381M 351M 318M 595M 40.49B 604M 4.19B 1.67B 21.19B 1.6B 1.56B 67.12B 534M 478M 441M 399M 746M 50.84B 759M 5.26B 2.1B 26.61B 2B 1.96B 84.27B
Net Debt 49.62M 44.45M 41M 37.11M 69.39M 4.73B 70.51M 489M 195M 2.47B 186M 182M 7.83B -322M -289M -266M -241M -451M -30.7B -458M -3.18B -1.27B -16.07B -1.21B -1.18B -50.89B
Projected Income Statement - Annual - Insulet Corporation
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
31/10/26 USD 152.84 +0.22% 72,347
29/10/26 USD 152.50 +2.40% 1,297,218
28/10/26 USD 148.93 -0.60% 1,035,225
27/10/26 USD 149.83 +0.38% 943,833
26/10/26 USD 149.26 +0.17% 1,525,635
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Insulet Corporation
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
152.50USD
Average target price
167.17USD
Spread / Average Target
+9.62%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Insulet Corporation
  1. Stock Market
  2. Stocks
  3. PODD Stock